论文部分内容阅读
本文将150例缺血性脑血管病患者分为尿激酶(urokinase,UK)治疗组与精制蝮蛇抗栓酶(SVATE-3)组(对照组)。UK组的治疗总有效率高于对照组(P值分别<0.05,0.01)。尤其是发病后12小时内开始应用UK组的治疗总有效率明显高于对照组(P<0.01),提示早期应用UK是治疗缺血性脑血管病、降低病死率、提高生存质量的关键。
In this paper, 150 patients with ischemic cerebrovascular disease were divided into urokinase (UK) treatment group and SVATE-3 (control group). The total effective rate of treatment in UK group was higher than that in control group (P <0.05, 0.01 respectively). In particular, the total effective rate of UK group started to be applied within 12 hours after onset was significantly higher than that of the control group (P <0.01), suggesting that the early application of UK is the key to the treatment of ischemic cerebrovascular disease, reduce the mortality and improve the quality of life.